Loading clinical trials...
Loading clinical trials...
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
NCT05758831 · Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
NCT06586177 · Relapsing-remitting Multiple Sclerosis
NCT05906992 · Relapsing-remitting Multiple Sclerosis
NCT05755061 · Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
NCT07517185 · Relapsing-remitting Multiple Sclerosis
The Queen Elizabeth Hospital
Woodville South, South Australia
North Gosford Private Hospital
Burrabil Avenue, Suite 17, Gosford
Strategic Health Evaluators
Chatswood
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions